Live and On-Demand Activities

Filter Activities

Clear

Beyond TNF Inhibitors: Latest and Emerging Evidence on Novel Cytokine-Modulating Strategies in the Treatment of Moderate to Severe Psoriasis

0.50 hr(s) | ABIM , CME , CPE , MOC , NCPD

Specialty: Psoriasis

Therapeutic Area(s): Dermatology

Release Date: June 17, 2021

Expiration Date: June 16, 2022

Location: Internet Activity Enduring

In this activity, an expert in dermatology discusses the latest evidence on novel cytokine-modulating strategies in the treatment of moderate to severe psoriasis.

Envisioning the Future of Emerging Nonfactor Therapies in Hemophilia A and B: The Art and Science of RNA Interference

0.50 hr(s) | CME

Specialty: Hemophilia

Therapeutic Area(s): Hematology, Benign

Release Date: June 16, 2021

Expiration Date: June 15, 2022

Location: Internet Activity Enduring

In this activity, an expert in hemophilia explores the evidence supporting novel, emerging hemophilia therapeutics and provides guidance on the implications of the evidence presented for real-world practice.

An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy

0.50 hr(s) | ABIM , CME , MOC

Specialty: Chronic Fibrosing Interstitial Lung Disease

Therapeutic Area(s): Pulmonology

Release Date: May 25, 2021

Expiration Date: May 24, 2022

Location: Internet Activity Enduring

In this activity, an expert in interstitial lung disease discusses the diagnosis of and novel and emerging therapies to treat chronic fibrosing interstitial lung disease.

Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management

1.50 hr(s) | ABIM , CME , CPE , MOC , NCPD

Specialty: Basal Cell Carcinoma

Therapeutic Area(s): Oncology

Release Date: June 4, 2021

Expiration Date: June 4, 2021

Location: Live Webcast

Basal cell carcinoma (BCC) is a commonly occurring skin malignancy that is easily treatable with surgery and/or radiation when detected at an early stage. However, advanced disease is typically associated with a poor prognosis and is often more challenging to treat, even with targeted agents (because of adverse events and the potential for acquired resistance). Advances in the understanding of BCC pathogenesis first suggested a role for immunotherapy via PD-1 blockade, and follow-up research has led to regulatory approval of immune treatment, including in patients who have progressed on or are unable to receive hedgehog pathway inhibitors. This “Seminars and Tumor Board” live web broadcast will provide an expert-led tour of the evidence that supports incorporating immunotherapy into existing treatment protocols for advanced BCC. Scientific lectures will be linked with practical, case-centered sessions designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards in order to clearly illustrate how oncologists can adapt their current practice and offer the power of immune-based treatment to patients with BCC. Register today to join us!

The Evolving Role of Oxybate Agents in the Management of Narcolepsy: A Visual Exploration of Individualized Care

0.50 hr(s) | CME

Specialty: Narcolepsy

Therapeutic Area(s): Family Medicine / Primary Care , Neurology

Release Date: May 18, 2021

Expiration Date: May 17, 2022

Location: Internet Activity Enduring

In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care.

Finding the Path to Improved Outcomes in Uncontrolled Persistent Asthma: Applying the Latest Clinical Evidence for Treatment Success

0.50 hr(s) | CME

Specialty: Asthma

Therapeutic Area(s): Pulmonology

Release Date: July 28, 2020

Expiration Date: July 27, 2021

Location: Internet Activity Enduring

In this activity, an expert in pulmonology discusses key issues in the diagnosis and treatment of patients with uncontrolled persistent asthma. Several case vignettes provide insights on assessing phenotype/endotype and eligibility for biologic therapy in these patients, in the context of common comorbidities and other patient-, disease-, and treatment-related factors.

Coronavirus Disease (COVID-19):Need-to-Know Information and Practical Guidance for Healthcare Professionals on the Front Lines of Patient Care

1.00 hr(s) | ABIM , CME , CPE , MOC , NCPD

Therapeutic Area(s): COVID , Immunology , Infectious Disease

Release Date: July 24, 2020

Expiration Date: July 23, 2021

Location: Internet Activity Enduring

In this activity, an expert in infectious diseases discusses guidance for healthcare professionals involved in the treatment of patients with COVID-19.

Teaming Up to Improve Liver Cancer Outcomes Through Locoregional and Systemic Therapeutic Strategies: A Multidisciplinary Tumor Board Guiding Optimal Care for Patients Along the Intermediate-to-Advanced Disease Continuum

hr(s) | CME

Specialty: Liver Cancer

Therapeutic Area(s): Hepatology , Oncology

Release Date: July 22, 2020

Expiration Date: July 21, 2021

Location: Internet Activity Enduring

Hepatocellular carcinoma (HCC) is a complex liver malignancy for which a variety of treatment modalities, based on disease stage and patient factors, are available. Traditionally, interventional radiologists (IR) have had a key role in managing intermediate-stage disease through the use of locoregional approaches, while oncologists have employed systemic therapy in the realm of advanced-stage disease. However, an improved understanding of HCC pathology has led to the realization that optimal approaches to selecting, combining, sequencing, and transitioning between different modalities has the potential to improve outcomes across disease settings, underscoring the importance of a multidisciplinary team-based approach to HCC management. As approvals for new drugs (eg, TKIs, antiangiogenic agents, immunotherapy, combinations) and positive clinical trial outcomes with novel multimodal strategies continue to impact the HCC treatment paradigm, clinical decision-making has become complicated, with many questions arising about optimal approaches to administering various therapies to the appropriate patient in a timely manner within a team-based care model. In this CME-certified online activity, a multidisciplinary panel of interventional radiology, hepatology, and oncology experts offers insights on how to navigate the intermediate- to advanced-stage HCC landscape in an era of evolving treatment—from use of modern IR approaches to newer systemic therapies and combination strategies—to provide the most benefit for patients with HCC.

1 2 3 4 5 14
Copy link
Powered by Social Snap